Growth hormone treatment and the risk of adolescent scoliosis: A large matched cohort study
Acta Paediatrica · 2023
DOI: 10.1111/apa.16749 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Acta Paediatrica, 2023. Verfasst von Tomer Ziv-Baran und 4 weiteren Autor:innen. Beteiligte Einrichtung: Sackler Faculty of Medicine, School of Public Health, Tel Aviv University, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Human Growth Hormone, Scoliosis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Aim
We aimed to evaluate the risk of developing adolescent scoliosis among recipients of recombinant human growth hormone (rhGH).
Methods
This registry‐based cohort study included 1314 individuals who initiated rhGH treatment since 2013, treated during 10–18 years of age for at least 6 months. This group was matched to a comparison group of 6570 individuals not treated with rhGH. Demographic and clinical information was extracted from the electronic database. The results are presented using hazard ratios (HR) and 95% confidence intervals (CI).
Results
During a median follow‐up of 4.2 years, 59 (4.5%) rhGH recipients and 141 individuals (2.1%) from the comparison group were diagnosed with adolescent scoliosis. The age at diagnosis did not differ between the groups (14.7 versus 14.3 years, p = 0.095). Patients treated with rhGH were more likely diagnosed with scoliosis (HR 2.12, 95% CI 1.55–2.88, p < 0.001). Among males, the risk was about three times greater in the treated versus the comparison group (HR 3.15, 95% CI 2.12–4.68, p < 0.001), while in females the risk was not increased (HR 1.12, 95% CI 0.72–2.04, p = 0.469).
Conclusions
Recombinant human growth hormone treatment was associated with an increased risk to be diagnosed with adolescent scoliosis in males. Scoliosis development should be monitored appropriately in rhGH recipients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sackler Faculty of Medicine, School of Public Health, Tel Aviv University, Tel Aviv, Israel.
- Sackler School of Medicine, University of Tel Aviv, Tel Aviv, Israel.
- Meuhedet Health Services, Tel Aviv, Israel.
- Pediatric Endocrinology and Diabetes Unit, The Edmond and Lily Safra Children's Hospital, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
- Department of Pediatric Orthopedics, The Edmond and Lily Safra Children's Hospital, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
ORCID-Profile: Yael Levy-Shraga
Zitieren
APA
Ziv-Baran, T., Modan-Moses, D., Zacay, G., Ackshota, N., & Levy-Shraga, Y. (2023). Growth hormone treatment and the risk of adolescent scoliosis: A large matched cohort study. Acta Paediatrica. https://doi.org/10.1111/apa.16749
Vancouver
Ziv-Baran T, Modan-Moses D, Zacay G, Ackshota N, Levy-Shraga Y. Growth hormone treatment and the risk of adolescent scoliosis: A large matched cohort study. Acta Paediatrica. 2023. doi:10.1111/apa.16749
BibTeX
@article{ZivBaran2023,
author = {Ziv-Baran, Tomer and Modan-Moses, Dalit and Zacay, Galia and Ackshota, Nissim and Levy-Shraga, Yael},
title = {Growth hormone treatment and the risk of adolescent scoliosis: A large matched cohort study},
journal = {Acta Paediatrica},
year = {2023},
doi = {10.1111/apa.16749}
}
EUVIMED